{"title":"Promising Findings in Myeloproliferative Neoplasms and AL Amyloidosis","authors":"","doi":"10.36000/hbt.oh.2022.13.077","DOIUrl":"https://doi.org/10.36000/hbt.oh.2022.13.077","url":null,"abstract":"","PeriodicalId":245688,"journal":{"name":"healthbook TIMES Oncology Hematology","volume":"101 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132497930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Emerging Treatment Options in Lung Cancer","authors":"A. Addeo","doi":"10.36000/hbt.oh.2022.13.076","DOIUrl":"https://doi.org/10.36000/hbt.oh.2022.13.076","url":null,"abstract":"KRYSTAL-1: Adagrasib demonstrated intracranial activity in previously treated patients with advanced NSCLC harboring a KRASG12C mutation The activity and safety of adagrasib, a covalent and highly selective inhibitor of KRASG12C, have been explored in patients with advanced KRASG12C-mutant solid tumors in the KRYSTAL-1 trial, with positive results previously reported for non-small cell lung cancer (NSCLC) from the phase I/Ib part of the study.1,2 In the registrational phase II cohort, patients with unresectable or metastatic KRASG12C-positive NSCLC, who were previously treated with a programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) inhibitor in combination or in sequence with chemotherapy, received adagrasib at a dose of 600 mg twice daily.3,4 Of note, patients with treated and stable central nervous system (CNS) metastases were eligible. The primary endpoint was objective response rate (ORR) and secondary endpoints included duration of response (DoR), progression-free survival (PFS), overall survival (OS) and safety.","PeriodicalId":245688,"journal":{"name":"healthbook TIMES Oncology Hematology","volume":"33 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127119657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Exciting New Data in Newly Diagnosed Multiple Myeloma","authors":"Dr Kaveh Samii","doi":"10.36000/hbt.oh.2022.13.080","DOIUrl":"https://doi.org/10.36000/hbt.oh.2022.13.080","url":null,"abstract":"The phase II 2018-04 study conducted by the Intergroupe Francophone du Myelome (IFM) group confirmed the efficacy and safety of quadruplet induction therapy in high-risk (HR), transplant-eligible (TE), newly diagnosed multiple myeloma patients (NDMM). 1 Previous studies investigating the triplet combination of carfilzomib, lenalidomide and dexamethasone (KRd) demonstrated a high efficacy with a favorable safety profile in TE-NDMM patients. 2 Furthermore, the addition of daratumumab (Dara) to front-line therapy resulted in a deep response and improved progression-free survival (PFS) in TE-NDMM patients, including HR patients. 3,4 The IFM study included TE-NDMM patients (age <66 years) with HR disease defined by cytogenic abnormalities such as translocation (t)(4;14), deletion (del)17p and t(14;16) detected by fluorescence in situ hybridization (FISH). The induction therapy consisted of 6 cycles of daratumumab, carfilzomib, lenalidomide and dexamethasone (Dara-KRd) given over 28 days, followed by stem cell collection and autologous stem cell transplantation (ASCT). Consolidation Dara-KRd was given in 4 cycles followed by a second round of ASCT, and finally, daratumumab and lenalidomide maintenance were adminis - tered over 2 years. The primary objective of this study was the feasibility of this treatment.","PeriodicalId":245688,"journal":{"name":"healthbook TIMES Oncology Hematology","volume":"4 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130514465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Highlights in Prostate Cancer from ASCO GU 2022","authors":"","doi":"10.36000/hbt.oh.2022.073","DOIUrl":"https://doi.org/10.36000/hbt.oh.2022.073","url":null,"abstract":"","PeriodicalId":245688,"journal":{"name":"healthbook TIMES Oncology Hematology","volume":"20 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127792219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Research for Tomorrow","authors":"","doi":"10.36000/hbt.oh.2022.12.075","DOIUrl":"https://doi.org/10.36000/hbt.oh.2022.12.075","url":null,"abstract":"","PeriodicalId":245688,"journal":{"name":"healthbook TIMES Oncology Hematology","volume":"238 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131512596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Highlights in Renal Cell Carcinoma from ASCO GU 2022","authors":"","doi":"10.36000/hbt.oh.2022.12.072","DOIUrl":"https://doi.org/10.36000/hbt.oh.2022.12.072","url":null,"abstract":"","PeriodicalId":245688,"journal":{"name":"healthbook TIMES Oncology Hematology","volume":"6 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124234656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Geriatric Oncology: Building Clinical Care for Swiss Patients","authors":"","doi":"10.36000/hbt.oh.2022.12.074","DOIUrl":"https://doi.org/10.36000/hbt.oh.2022.12.074","url":null,"abstract":"","PeriodicalId":245688,"journal":{"name":"healthbook TIMES Oncology Hematology","volume":"95 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132797047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Antibody-Drug Conjugates in Solid Tumors","authors":"","doi":"10.36000/hbt.oh.2022.11.062","DOIUrl":"https://doi.org/10.36000/hbt.oh.2022.11.062","url":null,"abstract":"","PeriodicalId":245688,"journal":{"name":"healthbook TIMES Oncology Hematology","volume":"115 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116619995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
